• JCR Pharmaceuticals secured UAE marketing authorization for IZCARGO, its blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome.
• Clearance marks IZCARGO’s first regulatory authorization outside Japan, where it launched in 2021; a global Phase III trial is ongoing.
• Taiba Middle East will handle sales distribution under a regional agreement as JCR pursues additional MENA approvals.
• JCR expects a minor impact on FY2026 consolidated results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JCR Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607211336BIZWIRE_USPR_____20260721_BW743638) on July 21, 2026, and is solely responsible for the information contained therein.